Latest News

New Zealand's Pharmac has announced a proposal to fund a new brand of ADHD medication, aiming to ease ongoing supply pressures and expand treatment options for people living with attention deficit hyperactivity disorder.

Sanofi has launched its global 'A Million Conversations' initiative in Australia, unveiling new research that highlights the extent of inequity and mistrust across the healthcare system.

“I’m super excited to take over the leadership for the ANZ team and advance together our Ipsen portfolio—especially bringing the new launches to Australian patients,” said Dagmar Tschoep.

Merck Healthcare has announced the appointment of Anna Porter as Director of Market Access, Government Affairs, and Communications for Australia and New Zealand.

A new nationwide telehealth service has launched to address the growing demand for ADHD diagnosis and care in Australia, where experts say adults remain significantly underserved despite soaring rates of prescriptions and referrals.

DHL Supply Chain Australia has begun construction on a significant new transport and warehousing hub in Edinburgh Park, South Australia, marking a substantial investment in the state’s logistics and supply chain capabilities.

CSL has announced a deal with Dutch biotech VarmX to advance a new therapy designed to restore blood clotting in patients taking Factor Xa inhibitors, a widely prescribed class of anticoagulants.

The most troubling aspect of the Medical Services Advisory Committee’s decision is not simply its rejection of Pompe disease for newborn screening, but its betrayal of the testimony of those living with the condition and their families.

For the committee, some of the reasons it used to reject adding Pompe disease to Australia’s newborn bloodspot screening programs are perversely the same as those it invoked to support the addition of Hurler (MPS I) and Hunter (MPS II) syndromes.

Tori Brown, currently President of the North Asia Pacific Hub and General Manager for ANZ, will relocate to Lilly’s US headquarters in Indianapolis to take on the role of Chief Marketing Officer, Cardiometabolic Health.

A recent Lighthouse publication from Macquarie University has found that aged care residents with dementia are prescribed antipsychotic medication at nearly twice the rate of those without dementia, despite years of reforms designed to reduce overmedication.

Australian cancer researchers are celebrating a landmark moment as a homegrown scientific discovery moves into late-stage clinical testing with Pfizer.